References
- Yin Y, Wunderink RG. MERS, SARS and other coronaviruses as causes of
pneumonia. Respirology. 2018;23(2):130–7.
- Xu J, Zhao S, Teng T, et al. Systematic Comparison of Two
Animal-to-Human Transmitted Human Coronaviruses: SARS-CoV-2 and
SARS-CoV. Viruses. 2020 Feb 22;12(2).
- Benvenuto D, Giovanetti M, Ciccozzi A, Spoto S, Angeletti S, Ciccozzi
M. The 2019-new coronavirus epidemic: Evidence for virus evolution. J
Med Virol. 2020;92(4):455–459. doi:10.1002/jmv.25688
- Diagnosis and Treatment Protocol for Novel Coronavirus Pneumonia
(Trial Version 7) (Released by National Health Commission & State
Administration of Traditional Chinese Medicine on March 3, 2020).
Available at:http://www.kankyokansen.org/uploads/uploads/files/jsipc/protocol_V7.pdf
- Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 Cell Entry
Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven
Protease Inhibitor [published online ahead of print, 2020 Mar 4].
Cell. 2020;S0092-8674(20)30229-4. doi:10.1016/j.cell.2020.02.052.
- Fehr AR, Perlman S. Coronaviruses: an overview of their replication
and pathogenesis. Methods Mol Biol. 2015;1282:1–23.
doi:10.1007/978-1-4939-2438-7_1
- Li Q, Guan X, Wu P, et al. Early Transmission Dynamics in Wuhan,
China, of Novel Coronavirus-Infected Pneumonia. N Engl J Med.
2020;382(13):1199–1207. doi:10.1056/NEJMoa2001316
- Guo YR, Cao QD, Hong ZS, Tan YY, Chen SD, Jin HJ, Tan KS, Wang DY, Yan
Y. The origin, transmission and clinical therapies on coronavirus
disease 2019 (COVID-19) outbreak - an update on the status. Mil Med
Res. 2020 Mar 13;7(1):11.
- Kruse RL. Therapeutic strategies in an outbreak scenario to treat the
novel coronavirus originating in Wuhan, China. F1000Res. 2020 Jan
31;9:72.
- Soliman EZ, Lundgren JD, Roediger MP, et al.; INSIGHT SMART Study
Group. Boosted protease inhibitors and the electrocardiographic
measures of QT and PR durations. AIDS. 2011 Jan 28;25(3):367-77.
- Dayer M R, Taleb-Gassabi S, Dayer M S. Lopinavir; A Potent Drug
against Coronavirus Infection: Insight from Molecular Docking Study,
Arch Clin Infect Dis. 2017;12(4):e13823.
- Arabi YM, Alothman A, Balkhy HH, et al.; The MIRACLE trial group.
Treatment of Middle East Respiratory Syndrome with a combination of
lopinavir-ritonavir and interferon-β1b (MIRACLE trial): study protocol
for a randomized controlled trial. Trials. 2018 Jan 30;19(1):81.
- Arabi YM, Alothman A, Balkhy HH, et al.; The Saudi Critical Care
Trials group. Treatment of Middle East respiratory syndrome with a
combination of lopinavir/ritonavir and interferon-β1b (MIRACLE trial):
statistical analysis plan for a recursive two-stage group sequential
randomized controlled trial. Trials. 2020 Jan 3;21(1):8.
- Cao B, Wang Y, Wen D, et al. A Trial of Lopinavir-Ritonavir in Adults
Hospitalized with Severe Covid-19 [published online ahead of print,
2020 Mar 18]. N Engl J Med. 2020;10.1056/NEJMoa2001282.
doi:10.1056/NEJMoa2001282
- Comparison of Lopinavir/Ritonavir or Hydroxychloroquine in Patients
With Mild Coronavirus Disease (COVID-19). Available at:https://clinicaltrials.gov/ct2/show/NCT04307693
- https://www.aifa.gov.it/-/aggiornamento-sui-farmaci-resi-disponibili-per-covid-19-al-di-fuori-delle-indicazioni-terapeutiche
- Sheahan TP, Sims AC, Leist SR, et al. Comparative therapeutic efficacy
of remdesivir and combination lopinavir, ritonavir, and interferon
beta against MERS-CoV. Nat Commun 2020;11:222.
- De Wit E, Feldmann F, Cronin J, et al. Prophylactic and Therapeutic
Remdesivir (GS-5734) Treatment in the Rhesus Macaque Model of MERS-CoV
Infection. PNAS Latest Articles 2020.
- Agostini ML, Andres EL, Sims AC, et al. Coronavirus Susceptibility to
the Antiviral Remdesivir (GS-5734) Is Mediated by the Viral Polymerase
and the Proofreading Exoribonuclease. mBio. 2018;9(2):e00221-18.
Published 2018 Mar 6. doi:10.1128/mBio.00221-18
- Wang M, Cao R, Zhang L, et al. Remdesivir and chloroquine effectively
inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Cell Res. 2020;30(3):269–271. doi:10.1038/s41422-020-0282-0
- Severe 2019-nCoV Remdesivir RCT. Available at:https://clinicaltrials.gov/ct2/show/NCT04257656?cond=NCT04257656&draw=1&rank=1
- Study to Evaluate the Safety and Antiviral Activity of Remdesivir
(GS-5734™) in Participants With Moderate Coronavirus Disease
(COVID-19) Compared to Standard of Care Treatment. Available at:https://clinicaltrials.gov/ct2/show/NCT04292730?cond=NCT04292730&draw=2&rank=1
- https://www.lanazione.it/cronaca/coronavirus-disputa-farmaco-sperimentale-1.5053379
- https://www.adnkronos.com/fatti/cronaca/2020/03/24/coronavirus-antivirale-remdesivir-sperimentato-centri-italiani_Bg7OlRzi11VIFVY1gSsD1K.html
- Holshue ML, De Bolt C, Lindquist S, et al. First case of 2019 novel
coronavirus in the United States. March 5, 2020. N Engl J Med 2020;
382:929-936.
- Furuta Y, Komeno T, Nakamura T. Favipiravir (T-705), a broad spectrum
inhibitor of viral RNA polymerase. Proc Jpn Acad Ser B Phys Biol Sci.
2017;93(7):449-463. doi: 10.2183/pjab.93.027.
- Delang L, Abdelnabi R, Neyts J. Favipiravir as a potential counter
measure against neglected and emerging RNA viruses. Antiviral Res.
2018 May;153:85-94. doi: 10.1016/j.antiviral.2018.03.003.
- https://asia.nikkei.com/Spotlight/Coronavirus/China-says-Japan-developed-drug-Avigan-works-against-coronavirus
- https://www.medrxiv.org/content/10.1101/2020.03.17.20037432v1
- Favipiravir Combined With Tocilizumab in the Treatment of Corona Virus
Disease 2019. Available at:https://clinicaltrials.gov/ct2/show/NCT04310228
- https://www.aifa.gov.it/-/favipiravir-aggiornamento-della-valutazione-della-cts
- Deeks ED. Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide: A
Review in HIV-1 Infection. Drugs. 2018 Jul;78(10):1013-1024.
- Lin S, Shen R, He J, Li X, Guo X. Molecular Modeling Evaluation of the
Binding Effect of Ritonavir, Lopinavir and Darunavir to Severe Acute
Respiratory Syndrome Coronavirus 2 Proteases. bioRxiv
2020.01.31.929695.
- Omotuyi OI, Nash O, Ajiboye BO, et al. Darunavir Disrupts Critical
Nodes in Metastable 2019-nCoV-RBD/ACE-2 Complex. Preprints
2020.2020030125
- Treatment of COVID-19 Cases and Chemoprophylaxis of Contacts as
Prevention (HCQ4COV19). Available at:https://clinicaltrials.gov/ct2/show/NCT04304053
- Efficacy and Safety of Darunavir and Cobicistat for Treatment of
Pneumonia Caused by 2019-nCoV (DACO-nCoV). Available at:https://clinicaltrials.gov/ct2/show/NCT04252274
- COVID-19 Registered Trials – and analysis. Available at:
https://www.cebm.net/covid-19/registered-trials-and-analysis/
- Elfiky AA. Ribavirin, Remdesivir, Sofosbuvir, Galidesivir, and
Tenofovir against SARS-CoV-2 RNA dependent RNA polymerase (RdRp): A
molecular docking study [published online ahead of print, 2020 Mar
25]. Life Sci. 2020;117592. doi:10.1016/j.lfs.2020.117592
- Wang D, Hu B, Hu C et al. Clinical characteristics of 138 hospitalized
patients with 2019 novel coronavirus–infected pneumonia in Wuhan,
China. JAMA. 2020; (published online Feb 7.)
DOI:10.1001/jama.2020.1585
- Zhou Y, Vedantham P, Lu K, et al. Protease inhibitors targeting
coronavirus and filovirus entry. Antiviral Res. 2015;116:76–84.
doi:10.1016/j.antiviral.2015.01.011
- https://clinicaltrials.gov/ct2/show/NCT04321096?term=camostat&
- https://www.eurekalert.org/pub_releases/2020-03/tiom-nie032420.php
- Ota S, Hara Y, Kanoh S, et al. Acute eosinophilic pneumonia caused by
camostat mesilate: The first case report. Respir Med Case Rep.
2016;19:21–23. Published 2016 Jun 16. doi:10.1016/j.rmcr.2016.06.005
- Bian HJ, Zheng ZH, Wei D, Zhang Z, Kang WK et al. Meplazumab
treats COVID-19 pneumonia: an open-labelled, concurrent controlled
add-on clinical trial . MedRxiv, March 24, 2020.
- Clinical Study of Anti-CD147 Humanized Meplazumab for Injection to
Treat With 2019-nCoV Pneumonia. ClinicalTrials.gov Identifier:
NCT04275245. Available at:
https://clinicaltrials.gov/ct2/show/NCT04275245?term=MEPLAZUMAB&draw=2&rank=1
- https://www.sciencedirect.com/science/article/pii/S0166354220302011
- Scott LJ. Tocilizumab: A Review in Rheumatoid Arthritis. Drugs. 2017
Nov;77(17):1865-1879.
- Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ; HLH
Across Speciality Collaboration, UK. COVID-19: consider cytokine storm
syndromes and immunosuppression. Lancet. 2020 Mar 16.
- Wen Zhang, Yan Zhao, Fengchun Zhang, Qian Wang, Taisheng Li, Zhengyin
Liu, Jinglan Wang, Yan Qin, Xuan Zhang, Xiaowei Yan, Xiaofeng Zeng,
Shuyang Zhang, The use of anti-inflammatory drugs in the treatment of
people with severe coronavirus disease 2019 (COVID-19): The experience
of clinical immunologists from China, Clinical Immunology, Volume 214,
2020, 08393, ISSN 1521-6616.
- Xu X, Han M, Li T, Sun W, et al. Effective Treatment of Severe
COVID-19 Patients with Tocilizumab. ChinaXiv:20200300026.
- https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001386-37/IT#A
- https://clinicaltrials.gov/ct2/show/NCT04320615
- Multicenter study on the efficacy and tolerability of tocilizumab in
the treatment of patients with COVID-19 pneumonia (TOCIVID-19).
Available on-line from https://clinicaltrials.gov/ct2/show/NCT04317092
- https://clinicaltrials.gov/ct2/show/NCT04324073?id=NCT04315298+OR+NCT04321993+OR+NCT04324073&draw=2&rank=1&load=cart
- https://clinicaltrials.gov/ct2/show/NCT04321993?id=NCT04315298+OR+NCT04321993+OR+NCT04324073&draw=2&rank=2&load=cart
- https://clinicaltrials.gov/ct2/show/NCT04315298?id=NCT04315298+OR+NCT04321993+OR+NCT04324073&draw=2&rank=3&load=cart
- Dong L, Hu S, Gao J. Discovering drugs to treat coronavirus disease
2019 (COVID-19). Drug Discov Ther. 2020;14(1):58-60.
- M. Frisk-Holmberg, Y. Bergqvist, U. Englund Chloroquine intoxication
[letter] Br. J. Clin. Pharmacol., 15 (1983), pp. 502-503,
10.1111/j.1365-2125.1983.tb01540.x
- E. Keyaerts, L. Vijgen, P. Maes, J. Neyts, M.V. Ranst In vitro
inhibition of severe acute respiratory syndrome coronavirus by
chloroquine Biochem. Biophys. Res. Commun., 323 (2004), pp. 264-268,
10.1016/j.bbrc.2004.08.085
- E. Keyaerts, S. Li, L. Vijgen, E. Rysman, J. Verbeeck, M. Van Ranst,
P. Maes Antiviral activity of chloroquine against human coronavirus
OC43 infection in newborn mice Antimicrob. Agents Chemother., 53
(2009), pp. 3416-3421, 10.1128/AAC.01509-08
- Y. Yan, Z. Zou, Y. Sun, X. Li, K.-F. Xu, Y. Wei, N. Jin, C. Jiang
Anti-malaria drug chloroquine is highly effective in treating avian
influenza A H5N1 virus infection in an animal model Cell Res., 23
(2013), pp. 300-302, 10.1038/cr.2012.165
- Gao J, Tian Z, Yang X. Breakthrough: Chloroquine phosphate has shown
apparent efficacy in treatment of COVID-19 associated pneumonia in
clinical studies. Biosci Trends. 2020;14(1):72–73.
- Inglot AD. Comparison of the antiviral activity in vitro of some
non-steroidal anti-inflammatory drugs. J Gen Virol.
1969;4(2):203–214.
- Vincent MJ, Bergeron E, Benjannet S, et al. Chloroquine is a potent
inhibitor of SARS coronavirus infection and spread. Virol J.
2005;2:69.
- Colson P, Rolain JM, Lagier JC, Brouqui P, Raoult D. Chloroquine and
hydroxychloroquine as available weapons to fight COVID-19. Int J
Antimicrob Agents. 2020 Mar 4;105932.
- https://www.aifa.gov.it/-/comunicazione-aifa-sull-utilizzo-di-clorochina-e-idrossiclorochina-nella-terapia-dei-pazienti-affetti-da-covid-19-informazioni-di-sicurezza
- Andreu JM, Timasheff SN.. Tubulin bound to colchicine forms polymers
different from microtubules. Proc Natl Acad Sci USA 1982;79:6753–6.
- Dalbeth N, Lauterio TJ, Wolfe HR.. Mechanism of action of colchicine
in the treatment of gout. Clin Ther 2014;36:1465–79.
- Chia EW, Grainger R, Harper JL.. Colchicine suppresses neutrophil
superoxide production in a murine model of gouty arthritis: a
rationale for use of low-dose colchicine. Br J Pharmacol
2009;153:1288–95.
- Li Z, Davis GS, Mohr C, Nain M, Gemsa D.. Inhibition of LPS-induced
tumor necrosis factor-alpha production by colchicine and other
microtubule disrupting drugs. Immunobiology 1996;195:624–39.
- Martinon F, Pétrilli V, Mayor A, Tardivel A, Tschopp J..
Gout-associated uric acid crystals activate the NALP3 inflammasome.
Nature 2006;440:237–41
- Colchicine Coronavirus SARS-CoV2 Trial (COLCORONA) (COVID-19).
Available at:https://clinicaltrials.gov/ct2/show/NCT04322682
- Mayence A, Vanden Eynde JJ. Baricitinib: A 2018 Novel FDA-Approved
Small Molecule Inhibiting Janus Kinases. Pharmaceuticals (Basel).
2019;12(1):37. Published 2019 Mar 12. doi:10.3390/ph12010037
- Richardson P, Griffin I, Tucker C, Smith D, Oechsle O, Phelan A,
Stebbing J. Baricitinib as potential treatment for 2019-nCoV acute
respiratory disease. Lancet. 2020 Feb 15;395(10223):e30-e31
- https://clinicaltrials.gov/ct2/show/NCT04321993?cond=Coronavirus+Infection&intr=Baricitinib&draw=2&rank=1
- Stebbing J, Phelan A, Griffin I, Tucker C, Oechsle O, Smith D,
Richardson P. COVID-19: combining antiviral and anti-inflammatory
treatments. Lancet Infect Dis. 2020 Feb 27. pii:
S1473-3099(20)30132-8.
- Favalli EG, Ingegnoli F, De Lucia O, Cincinelli G, Cimaz R, Caporali
R. COVID-19 infection and rheumatoid arthritis: Faraway, so close!
Autoimmun Rev. 2020 Mar 20:102523.
- Bekerman E, Neveu G, Shulla A, et al. Anticancer kinase inhibitors
impair intracellular viral trafficking and exert broad-spectrum
antiviral effects. J Clin Invest 2017; 127: 1338–52.
- Leuchte, H. H., Baezner, C., Baumgartner, R. A., Bevec, D., Bacher,
G., Neurohr, C., & Behr, J. (2008). Inhalation of vasoactive
intestinal peptide in pulmonary hypertension. The European respiratory
journal, 32(5), 1289–94
- Petkov, V., Mosgoeller, W., Ziesche, R., Raderer, M., Stiebellehner,
L., Vonbank, K., et al. (2003). Vasoactive intestinal peptide as a new
drug for treatment of primary pulmonary hypertension. The Journal of
clinical investigation, 111(9), 1339–46.
- Said, S. I. (2012). Vasoactive intestinal peptide in pulmonary
arterial hypertension. American journal of respiratory and critical
care medicine, 185(7), 786; author reply 786.
- ClinicalTrials.gov – Identifier: NCT04311697
(clinicaltrials.gov/ct2/show/NCT04311697)
- Ip WK, Chan KH, Law HK, Tso GH, Kong EK, Wong WH, To YF, Yung RW, Chow
EY, Au KL, Chan EY, Lim W, Jensenius JC, Turner MW, Peiris JS, Lau YL
J Infect Dis. 2005 May 15; 191(10):1697-704.
- Yuan FF, Tanner J, Chan PK, Biffin S, Dyer WB, Geczy AF, Tang JW, Hui
DS, Sung JJ, Sullivan JS Tissue Antigens. 2005 Oct; 66(4):291-6.
- Gralinski LE, Sheahan TP, Morrison TE, Menachery VD, Jensen K, Leist
SR, Whitmore A, Heise MT, Baric RS. Complement Activation Contributes
to Severe Acute Respiratory Syndrome Coronavirus Pathogenesis. mBio.
2018 Oct 9;9(5).
- ClinicalTrials.gov – Identifier: NCT04288713
(https://clinicaltrials.gov/ct2/show/NCT04288713)
- Efficacy and Safety of Emapalumab and Anakinra in Reducing
Hyperinflammation and Respiratory Distress in Patients With COVID-19
Infection. Available at:https://clinicaltrials.gov/ct2/show/NCT04324021
- http://www.salute.gov.it/portale/nuovocoronavirus/dettaglioNotizieNuovoCoronavirus.jsp?lingua=italiano&menu=notizie&p=dalministero&id=4344
- Stockman LJ, Bellamy R, Garner P. SARS: systematic review of treatment
effects. PLoS Med. 2006;3(9):e343. Epub 2006/09/14. doi:
10.1371/journal.pmed.0030343. PubMed PMID: 16968120; PMCID:
PMC1564166.
- Rodrigo C, Leonardi-Bee J, Nguyen-Van-Tam J, Lim WS. Corticosteroids
as adjunctive therapy in the treatment of influenza. Cochrane Database
Syst Rev. 2016;3:CD010406. Epub 2016/03/08. doi:
10.1002/14651858.CD010406.pub2. PubMed PMID: 26950335.
- Delaney JW, Pinto R, Long J, Lamontagne F, Adhikari NK, Kumar A et al.
The influence of corticosteroid treatment on the outcome of influenza
A(H1N1pdm09)-related critical illness. Crit Care. 2016;20:75. Epub
2016/04/03. doi: 10.1186/s13054-016-1230-8. PubMed PMID: 27036638;
PMCID: PMC4818504
- https://www.who.int/docs/default-source/coronaviruse/clinical-management-of-novel-cov.pdf
- Ling Y, Xu SB, Lin YX, Tian D, et al. Persistence and clearance of
viral RNA in 2019 novel coronavirus disease rehabilitation patients.
Chin Med J(Engl).2020 Feb 28.
- Sung JJ, Wu A, Joynt GM, Yuen KY, Lee N, Chan PK, et al. Severe acute
respiratory syndrome: report of treatment and outcome after a major
outbreak. Thorax 2004; 59: 414-420. doi: 10.1136/thx.2003.014076.
- Wong CK, Lam CW, Wu AK, Ip WK, Lee NL, Chan IH, et al. Plasma
inflammatory cytokines and chemokines in severe acute respiratory
syndrome. Clin Exp Immunol 2004; 136: 95-103. doi:
10.1111/j.1365-2249.2004.02415.x.
- Zhu L, Xu X, Ma K, Yang J, Guan H, Chen S, Chen Z, Chen G. Successful
recovery of COVID-19 pneumonia in a renal transplant recipient with
long-term immunosuppression. Am J Transplant. 2020 Mar 17. doi:
10.1111/ajt.15869.
- Markham A, Keam SJ. Camrelizumab: First Global Approval. Drugs. 2019
Aug;79(12):1355-1361.
- Zhu XD, Sun HC. Emerging agents and regimens for hepatocellular
carcinoma. J Hematol Oncol. 2019 Oct 26;12(1):110.
- https://clinicaltrials.gov/ct2/show/NCT04268537
- U. S. Food and Drug Administration. Center for Drug Evaluation and
Research. Final Labeling Text, BL125085 Supplement, 2008.
- The European Medicines Agency. European Public Assessment Report.
Avastin Product Information. Avastin-H-C-582-II-23, August 2008
- Barratt S, Medford AR, Millar AB. Vascular endothelial growth factor
in acute lung injury and acute respiratory distress syndrome.
Respiration. 2014;87(4):329-42. doi: 10.1159/000356034.
- Bevacizumab in Severe or Critically Severe Patients with COVID-19
Pneumonia-RCT (BEST-RCT) ClinicalTrials.gov:
https://clinicaltrials.gov/ct2/show/NCT04305106?cond=COVID-19&draw=10
- Bevacizumab in Severe or Critical Patients With COVID-19 Pneumonia
(BEST-CP). ClinicalTrials.gov:https://clinicaltrials.gov/ct2/show/NCT04275414
- Moreira AL, Corral LG, Ye W, Johnson B, Stirling D, Muller GW,
Freedman VH, Kaplan G. Thalidomide and thalidomide analogs reduce HIV
type 1 replication in human macrophages in vitro. AIDS Res Hum
Retroviruses. 1997 Jul 1;13(10):857-63.
- Kwon HY, Han YJ, Im JH, Baek JH, Lee JS. Two cases of immune
reconstitution inflammatory syndrome in HIV patients treated with
thalidomide. Int J STD AIDS. 2019 Oct;30(11):1131-1135
- Mazzoccoli L, Cadoso SH, Amarante GW, de Souza MV, Domingues R,
Machado MA, de Almeida MV, Teixeira HC. (2012) Novel thalidomide
analogues from diamines inhibit pro-inflammatory cytokine production
and CD80 expression while enhancing IL-10. Biomed. Pharmacother., 66
(5): 323-9.
- https://clinicaltrials.gov/ct2/show/NCT04273529
- https://clinicaltrials.gov/ct2/show/record/NCT04273529
- https://www.smartpatients.com/trials/NCT04280588
- Chinese Clinical Trial Register (ChiCTR)-The World Health Organization
International Clinical Trials Registered Organization Registered
Platform. Available at: http://www.chictr.org.cn/abouten.aspx .
- http://apjai-journal.org/wp-content/uploads/2020/03/5_AP-200220-0773.pdf
- Atluri S, Manchikanti L, Hirsch JA. Expanded Umbilical Cord
Mesenchymal Stem Cells (UC-MSCs) as a Therapeutic Strategy in Managing
Critically Ill COVID-19 Patients: The Case for Compassionate Use. Pain
Physician. 2020 Mar;23(2):E71-E83. PubMed PMID: 32214286.
- Jawhara S. Could Intravenous Immunoglobulin Collected from Recovered
Coronavirus Patients Protect against COVID-19 and Strengthen the
Immune System of New Patients? Int J Mol Sci. 2020 Mar 25;21(7). pii:
E2272. doi: 10.3390/ijms21072272. PubMed PMID: 32218340.
- Shang W, Yang Y, Rao Y, Rao X. The outbreak of SARS-CoV-2 pneumonia
calls for viral vaccines. NPJ Vaccines. 2020;5:18. Published 2020 Mar
6. doi:10.1038/s41541-020-0170-0
- https://www.who.int/blueprint/priority-diseases/key-action/novel-coronavirus-landscape-ncov.pdf?ua=1
- https://www.sciencedaily.com/releases/2020/04/200402144508.htm
- https://science.sciencemag.org/content/368/6486/14
- The Liverpool Drug Interaction Group, Department of Pharmacology at
University of Liverpool. COVID-19 Drug Interactions. Available
on-line from: https://www.covid19-druginteractions.org
- Chen H, Guo Juanjuan, Wang C et al. Clinical characteristics and
intrauterine vertical transmission potential of COVID-19 infection in
nine pregnant women: a retrospective review of medical records.
Lancet. 2020.
- https://www.ema.europa.eu/en/documents/medicine-outside-eu/aluvia-product-information_en.pdf
- https://www.ema.europa.eu/en/documents/other/summary-compassionate-use-remdesivir-gilead_en.pdf
- https://www.ema.europa.eu/en/documents/product-information/rezolsta-epar-product-information_en.pdf
- https://www.ema.europa.eu/en/documents/product-information/rezolsta-epar-product-information_en.pdf
- http://www.shijiebiaopin.net/upload/product/201272318373223.PDF
- https://farmaci.agenziafarmaco.gov.it/aifa/servlet/PdfDownloadServlet?pdfFileName=footer_008055_013967_RCP.pdf&retry=0&sys=m0b1l3
- https://farmaci.agenziafarmaco.gov.it/aifa/servlet/PdfDownloadServlet?pdfFileName=footer_001565_009964_RCP.pdf&retry=0&sys=m0b1l3
- https://www.ema.europa.eu/en/documents/product-information/olumiant-epar-product-information_en.pdf
- https://www.ema.europa.eu/en/documents/product-information/soliris-epar-product-information_en.pdf